TIDMSAR
RNS Number : 1519Q
Sareum Holdings PLC
17 October 2019
(AIM: SAR)
17 October 2019
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum's TYK2/JAK1 Inhibitor SDC-1802 demonstrates anti-tumour
activity in multiple cancer disease models via a novel
immunotherapeutic mechanism of action
Abstract for presentation at AACR-NCI-EORTC cancer conference
published
Sareum Holdings plc, the specialist small molecule drug
development business, is pleased to announce that, further to its
announcement of 27 September 2019, the abstract for the poster that
the Company will present at the American Association for Cancer
Research (AACR) National Cancer Institute (NCI) European
Organisation for Research and Treatment of Cancer (EORTC)
International Conference, has now been published on the conference
website. The abstract can be viewed in full using the link
below:
Poster Session C: Therapeutic Agents - Small Molecule Kinase
Inhibitors, 12.30-4.00pm
https://eventpilotadmin.com/web/page.php?page=IntHtml&project=AACR19MT&id=363
"Immunotherapeutic effects of the TYK2 inhibitor SAR-20351 in
syngeneic tumour models."
Abstract C086, Poster Board #86
The Conference will be held 26-30 October 2019 in Boston, USA
and Sareum's CEO, Dr Tim Mitchell, will present the poster on 29
October 2019. The poster will describe how SDC-1802 (formerly known
as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by
Sareum, significantly reduces tumour growth in disease models of
cancers of the pancreas, colon, skin and kidney, plus B-cell
lymphoma.
The studies determined that SDC-1802 induces this anti-cancer
activity through a novel immunotherapeutic mechanism of action that
stimulates the local immune system to attack cancer cells. These
positive results were seen when SDC-1802/SAR-20351 was dosed
orally, both as a monotherapy and in combination with chemotherapy.
These data provide support for TYK2/JAK1 inhibition as a
potentially powerful new immunotherapy approach and for the further
development of SDC-1802 as a novel cancer therapeutic.
Sareum's CEO, Dr Tim Mitchell, commented: "We are looking
forward to presenting the data showing how our TYK2/JAK1 inhibitor,
SDC-1802, induces a significant reduction of tumour growth in
preclinical models of many cancer types via a novel
immunotherapeutic mechanism of action. These data suggest that our
TYK2/JAK1 inhibitor could also offer the additional potential
advantage of oral delivery. This contrasts with currently marketed
cancer immunotherapies, which can only be dosed by injection. We
are delighted to be presenting at this important international
cancer conference and engaging with interested parties from the
many leading pharma and biotech companies that attend this
event."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generates value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases
(SDC-1801) and cancers (SDC-1802). The Company is targeting first
human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients. SRA737 was discovered and initially
developed by scientists at The Institute of Cancer Research in
collaboration with Sareum, and with funding from Cancer Research
UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra
Oncology, in a $328.5m plus royalties licence deal, with Sareum
eligible to receive 27.5% of all payments to CPF under the
agreement.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
Cancer Immunotherapy, also known as immuno-oncology, is a form
of cancer treatment that uses the power of the body's own immune
system to prevent, control, and eliminate cancer. Cancer
Immunotherapy can:
-- Educate the immune system to recognise and attack specific cancer cells;
-- Boost immune cells to help them eliminate cancer; and
-- Provide the body with additional components to enhance the immune response.
Unleashing the power of the immune system is considered to be a
smart way to fight cancer because:
-- The immune system is precise, so it is possible for it to
target cancer cells exclusively while sparing healthy cells;
-- The immune system can adapt continuously and dynamically,
just like cancer does, so if a tumour manages to escape detection,
the immune system can re-evaluate and launch a new attack; and
-- The immune system's "memory" allows it to remember what
cancer cells look like, so it can target and eliminate the cancer
if it returns.
(Source: The Cancer Research Institute,
www.cancerresearch.org)
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESMFBMTMBIBTAL
(END) Dow Jones Newswires
October 17, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sareum (LSE:SAR)
Storico
Da Apr 2023 a Apr 2024
